Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04553133 | PF-07104091 as a Single Agent and in Combination Therapy | active not recruiting | Phase 2 | 157 | PfizerINDUSTRY | 4 | May 6, 2026 | clinicaltrials |
| NCT05557591 | A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) | active not recruiting | Phase 2 | 51 | Regeneron PharmaceuticalsINDUSTRY | 7 | May 6, 2026 | clinicaltrials |
| NCT04430725 | Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study | active not recruiting | — | 74 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04564157 | New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy(NADIM-ADJUVANT) | active not recruiting | Phase 3 | 210 | Fundación GECPOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05012254 | Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases(NIVIPI-Brain) | active not recruiting | Phase 2 | 71 | Fundación GECPOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05138900 | A Pilot Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) in Central Non-Small Cell Lung Cancer | active not recruiting | N/A | 30 | Roswell Park Cancer InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05684276 | DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors(DUMAS) | active not recruiting | Phase 2 | 22 | Fundación GECPOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06268613 | A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy | active not recruiting | Phase 1 | 163 | Samsung Bioepis Co., Ltd.INDUSTRY | 4 | May 5, 2026 | clinicaltrials |
| NCT01888601 | TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)(TRACERx) | active not recruiting | — | 814 | University College, LondonOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05491811 | Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation(EAGLE) | active not recruiting | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT05195632 | Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer(OCEANII) | active not recruiting | Phase 2 | 63 | Pierre Fabre MedicamentINDUSTRY | 2 | May 1, 2026 | clinicaltrials |
| NCT03838159 | NADIM II: Neo-Adjuvant Immunotherapy(NADIMII) | active not recruiting | Phase 2 | 90 | Fundación GECPOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT02495896 | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 61 | University of Southern CaliforniaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT02589522 | Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors | active not recruiting | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2026 | clinicaltrials |
| NCT03122717 | Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT03586453 | Osimertinib In EGFR Mutant Lung Cancer | active not recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05765825 | Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC | active not recruiting | Phase 2 | 61 | Sichuan UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06117774 | Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)(DeLLphi-306) | active not recruiting | Phase 3 | 404 | AmgenINDUSTRY | 27 | Apr 29, 2026 | clinicaltrials |
| NCT06300424 | Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC(NEOVADE) | active not recruiting | Phase 2 | 32 | Guangdong Provincial People's HospitalOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06477523 | Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC | active not recruiting | Phase 1 / Phase 2 | 57 | Sichuan UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT02279004 | A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care | active not recruiting | — | 840 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03969823 | Whole Genomic Landscape of Advanced EGFR-mutant NSCLC | active not recruiting | N/A | 148 | Seoul National University HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05782361 | POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC(POTENT) | active not recruiting | Phase 1 | 19 | Institute of Cancer Research, United KingdomOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05882513 | Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer | active not recruiting | Phase 2 | 36 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06736418 | Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy | active not recruiting | Phase 1 | 17 | Abdera Therapeutics Inc.INDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05617963 | Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax(DURVALUNG) | active not recruiting | Phase 2 | 100 | UNICANCEROTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04701307 | Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas | active not recruiting | Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05687266 | Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations(AVANZAR) | active not recruiting | Phase 3 | 1,350 | AstraZenecaINDUSTRY | 23 | Apr 22, 2026 | clinicaltrials |
| NCT03909334 | Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 2 | 160 | Xiuning LeOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05633602 | Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study | active not recruiting | Phase 3 | 838 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06382129 | A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) | active not recruiting | Phase 3 | 698 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06500026 | A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) | active not recruiting | Phase 3 | 722 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)(LIBRETTO-001) | active not recruiting | Phase 1 / Phase 2 | 857 | Eli Lilly and CompanyINDUSTRY | 16 | Apr 16, 2026 | clinicaltrials |
| NCT03637816 | Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 2 / Phase 3 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03731585 | Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment | active not recruiting | N/A | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05470595 | A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung(LCNEC-ALPINE) | active not recruiting | Phase 2 | 67 | Technische Universität DresdenOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05635708 | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 400 | BeiGeneINDUSTRY | 15 | Apr 15, 2026 | clinicaltrials |
| NCT06933329 | Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 73 | BicycleTx LimitedINDUSTRY | 2 | Apr 15, 2026 | clinicaltrials |
| NCT03540420 | Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer(ACHILES) | active not recruiting | Phase 2 | 212 | Norwegian University of Science and TechnologyOTHER | 6 | Apr 13, 2026 | clinicaltrials |
| NCT05215769 | A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer | active not recruiting | N/A | 243 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05553834 | PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung | active not recruiting | Phase 2 | 60 | Duke UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05595460 | Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC | active not recruiting | Phase 1 | 21 | RayzeBio, Inc.INDUSTRY | 2 | Apr 13, 2026 | clinicaltrials |
| NCT05735327 | A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY(ENTIRETY) | active not recruiting | — | 50 | TakedaINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06282874 | Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases | active not recruiting | Phase 4 | 41 | Guangdong Association of Clinical TrialsOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06099782 | A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) | active not recruiting | Phase 2 | 147 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Apr 8, 2026 | clinicaltrials |
| NCT04560972 | LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer | active not recruiting | Phase 1 | 3 | City of Hope Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05183932 | Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer(SORT) | active not recruiting | — | 446 | Washington University School of MedicineOTHER | 2 | Apr 7, 2026 | clinicaltrials |
| NCT03916627 | Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | active not recruiting | Phase 2 | 65 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05703269 | Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy(HYPOGRYPHE) | active not recruiting | N/A | 58 | Wake Forest University Health SciencesOTHER | 1 | Apr 6, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 6, 2026source: clinicaltrials